Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic

Laboratory Investigation

Volumn 95, Issue 4, 2015, Pages 385-396

  Carvajal Hausdorf, Daniel E ^a   Schalper, Kurt A ^a   Neumeister, Veronique M ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AVIDIN; BIOLOGICAL MARKER; BIOTIN; DIAMINOBENZIDINE; FLUORESCENT DYE; MESSENGER RNA; OLIGONUCLEOTIDE; PROTEIN; RNA; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER TISSUE; CLINICAL LABORATORY; DIAGNOSTIC KIT; DIAGNOSTIC TEST; FLUORESCENCE; GENE AMPLIFICATION; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; STANDARDIZATION; TISSUE STRUCTURE; VALIDITY; CHEMISTRY; FEMALE; MALE; MASS SPECTROMETRY; MOLECULAR IMAGING; NEOPLASMS; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MOLECULAR IMAGING; NEOPLASMS;

EID: 84926336637     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.157     Document Type: Article

References (109)

1. Koh J, Go H, Kim MY, et al. A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers. Histopathology 2014;65:868-878.
2. van der Loos CM. Chromogens in multiple immunohistochemical staining used for visual assessment and spectral imaging: the colorful future. J Histotechnol 2010;33:31-40.
3. Graham Jr. RC, Karnovsky MJ. The early stages of absorption of injected horseradish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique. J Histochem Cytochem 1966;14:291-302.
4. Tubbs RR, Sheibani K, Deodhar SD, et al. Enzyme immunohistochemistry: review of technical aspects and diagnostic applications. Cleve Clin Q 1981;48:245-281.
5. Nakane PK, Pierce Jr. GB. Enzyme-labeled antibodies: preparation and application for the localization of antigens. J Histochem Cytochem 1966;14:929-931.
6. Speel EJ. Robert Feulgen Prize Lecture 1999. Detection and amplification systems for sensitive, multiple-target DNA and RNA in situ hybridization: looking inside cells with a spectrum of colors. Histochem Cell Biol 1999;112:89-113.
7. Rimm DL. What brown cannot do for you. Nat Biotechnol 2006;24: 914-916.
8. Nie S, Zare RN. Optical detection of single molecules. Annu Rev Biophys Biomol Struct 1997;26:567-596.
9. Waggoner A. Fluorescent labels for proteomics and genomics. Curr Opin Chem Biol 2006;10:62-66.
10. Coto-Garcia AM, Sotelo-Gonzalez E, Fernandez-Arguelles MT, et al. Nanoparticles as fluorescent labels for optical imaging and sensing in genomics and proteomics. Anal Bioanal Chem 2011;399:29-42.
11. Xing Y, Chaudry Q, Shen C, et al. Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc 2007; 2:1152-1165.
12. Levenson RM. Spectral imaging perspective on cytomics. Cytometry A 2006;69:592-600.
13. Adams JC. Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J Histochem Cytochem 1992;40: 1457-1463.
14. Hunyady B, Krempels K, Harta G, et al. Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. J Histochem Cytochem 1996;44:1353-1362.
15. Tsutsumi Y, Serizawa A, Kawai K. Enhanced polymer one-step staining (EPOS) for proliferating cell nuclear antigen (PCNA) and Ki-67 antigen: application to intra-operative frozen diagnosis. Pathol Int 1995; 45:108-115.
16. Mason DY, Sammons R. Alkaline phosphatase and peroxidase for double immunoenzymatic labelling of cellular constituents. J Clin Pathol 1978;31:454-460.
17. Guesdon JL, Ternynck T, Avrameas S. The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem 1979;27:1131-1139.
18. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-229.
19. Sternberger LA, Hardy Jr. PH, Cuculis JJ, et al. The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem 1970;18:315-333.
20. Chilosi M, Lestani M, Pedron S, et al. A rapid immunostaining method for frozen sections. Biotech Histochem 1994;69:235-239.
21. Sabattini E, Bisgaard K, Ascani S, et al. The EnVision+ + system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol 1998;51:506-511.
22. Nallur G, Luo C, Fang L, et al. Signal amplification by rolling circle amplification on DNA microarrays. Nucleic Acids Res 2001;29:E118.
23. Gusev Y, Sparkowski J, Raghunathan A, et al. Rolling circle amplification: a new approach to increase sensitivity for immunohistochemistry and flow cytometry. Am J Pathol 2001;159:63-69.
24. Angel CE, George E, Brooks AE, et al. Cutting edge: CD1a+ antigenpresenting cells in human dermis respond rapidly to CCR7 ligands. J Immunol 2006;176:5730-5734.
25. Brown J, Wimberly H, Lannin DR, et al. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2014;20:5995-6005.
26. Farstad IN, Malavasi F, Haraldsen G, et al. CD38 is a marker of human lacteals. Virchows Arch 2002;441:605-613.
27. Hudson DL, Guy AT, Fry P, et al. Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 2001;49:271-278.
28. Gentry SM, Levenson RM. Biomedical applications of the informationefficient spectral imaging sensor (ISIS). Proc SPIE 3603, Systems and Technologies for Clinical Diagnostics and Drug Discovery II, 129 (21 April 1999); doi:10.1117/12.346734.
29. Levenson RM, Cronin PJ, Pankratov KK. Spectral imaging for brightfield microscopy. Proc SPIE 4959, Spectral Imaging: Instrumentation, Applications, and Analysis II, 27 (2 July 2003); doi:10.1117/12.485550.
30. Nadrigny F, Rivals I, Hirrlinger PG, et al. Detecting fluorescent protein expression and co-localisation on single secretory vesicles with linear spectral unmixing. Eur Biophys J 2006;35:533-547.
31. Dickinson ME, Bearman G, Tille S, et al. Multi-spectral imaging and linear unmixing add a whole new dimension to laser scanning fluorescence microscopy. Biotechniques 2001;31:12724-6, 8.
32. Mansfield JR, Hoyt C, Levenson RM. Visualization of microscopy-based spectral imaging data from multi-label tissue sections. Curr Protoc Mol Biol 2008) Chapter 14: Unit 14.9.
33. Gerdes MJ, Sevinsky CJ, Sood A, et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci USA 2013;110:11982-11987.
34. Schubert W, Dress A, Ruonala M, et al. Imaging cycler microscopy. Proc Natl Acad Sci USA 2014;111:E215.
35. Dabbs DJ. Diagnostic Immunohistochemistry. Elsevier Health Sciences; Philadelphia, PA, 2013.
36. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28: 2784-2795.
37. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.
38. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
39. Coons AH, Creech HJ, Jones RN. Immunological properties of an antibody containing a fluorescent group. Exp Biol Med 1941;47:200-202.
40. Marrack J. Nature of antibodies. Nature 1934;133:292-293.
41. Jensen EC. Types of imaging, Part 2: an overview of fluorescence microscopy. Anat Rec (Hoboken) 2012;295:1621-1627.
42. Spigel DR, Edelman MJ, O'Byrne K, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol 2014;32:5s.
43. Gustavson MD, Rimm DL, Dolled-Filhart M. Tissue microarrays: leaping the gap between research and clinical adoption. Personalized Med 2013;10:441-451.
44. Rojo MG, Bueno G, Slodkowska J. Review of imaging solutions for integrated quantitative immunohistochemistry in the Pathology daily practice. Folia Histochem Cytobiol 2009;47:349-354.
45. Schalper KA, Brown J, Carvajal-Hausdorf D, et al. Objective measurement and clinical significance of tumor infiltrating lymphocytes in non-small cell lung cell cancer (NSCLC). J Natl Cancer Inst; in press.
46. Schubert W, Bonnekoh B, Pommer AJ, et al. Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. Nat Biotechnol 2006;24:1270-1278.
47. Clarke GM, Zubovits JT, Shaikh KA, et al. A novel, automated technology for multiplex biomarker imaging and application to breast cancer. Histopathology 2014;64:242-255.
48. Angelo M, Bendall SC, Finck R, et al. Multiplexed ion beam imaging of human breast tumors. Nat Med 2014;20:436-442.
49. Giesen C, Wang HA, Schapiro D, et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods 2014;11:417-422.
50. Qian X, Lloyd RV. Recent developments in signal amplification methods for in situ hybridization. Diagn Mol Pathol 2003;12:1-13.
51. Yang H, Wanner IB, Roper SD, et al. An optimized method for in situ hybridization with signal amplification that allows the detection of rare mRNAs. J Histochem Cytochem 1999;47:431-446.
52. Cassidy A, Jones J. Developments in in situ hybridisation. Methods 2014;70:39-45.
53. Jehan Z, Uddin S, Al-Kuraya KS. In-situ hybridization as a molecular tool in cancer diagnosis and treatment. Curr Med Chem 2012;19: 3730-3738.
54. Kwon S. Single-molecule fluorescence in situ hybridization: quantitative imaging of single RNA molecules. BMB Rep 2013;46: 65-72.
55. Liehr T, Weise A, Hamid AB, et al. Multicolor FISH methods in current clinical diagnostics. Expert Rev Mol Diagn 2013;13:251-255.
56. Wang F, Flanagan J, Su N, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2012;14:22-29.
57. Raj A, Tyagi S. Detection of individual endogenous RNA transcripts in situ using multiple singly labeled probes. Methods Enzymol 2010;472:365-386.
58. Raj A, van den Bogaard P, Rifkin SA, et al. Imaging individual mRNA molecules using multiple singly labeled probes. Nat Methods 2008; 5:877-879.
59. Jakobsen MR, Bak RO, Andersen A, et al. IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. Proc Natl Acad Sci USA 2013;110:E4571-E4580.
60. Malone CD, Mestdagh C, Akhtar J, et al. The exon junction complex controls transposable element activity by ensuring faithful splicing of the piwi transcript. Genes Dev 2014;28:1786-1799.
61. McIsaac RS, Silverman SJ, Parsons L, et al. Visualization and analysis of mRNA molecules using fluorescence in situ hybridization in Saccharomyces cerevisiae. J Vis Exp; advance online publication, 14 January 2013; doi:10.3791/50382.
62. O'Grady T, Cao S, Strong MJ, et al. Global bidirectional transcription of the Epstein-Barr virus genome during reactivation. J Virol 2014;88: 1604-1616.
63. Pernicova Z, Slabakova E, Fedr R, et al. The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells. Mol Cancer 2014;13:113.
64. Rantala JK, Kwon S, Korkola J, et al. Expanding the diversity of imaging-based RNAi screen applications using cell spot microarrays. Microarrays 2013;2:97-114.
65. Vera M, Pani B, Griffiths LA, et al. The translation elongation factor eEF1A1 couples transcription to translation during heat shock response. eLife 2014;3:e03164.
66. Yang L, Lin C, Liu W, et al. ncRNA-and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell 2011;147:773-788.
67. Singel SM, Batten K, Cornelius C, et al. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways. Breast Cancer Res 2014;16:R28.
68. Singel SM, Cornelius C, Zaganjor E, et al. KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triplenegative breast cancer. Neoplasia 2014;16:247-256, 56.e2.
69. Darnell DK, Stanislaw S, Kaur S, et al. Whole mount in situ hybridization detection of mRNAs using short LNA containing DNA oligonucleotide probes. RNA 2010;16:632-637.
70. Robertson KL, Thach DC. LNA flow-FISH: a flow cytometryfluorescence in situ hybridization method to detect messenger RNA using locked nucleic acid probes. Anal Biochem 2009;390:109-114.
71. Gupta A, Mo YY. Detection of microRNAs in cultured cells and paraffinembedded tissue specimens by in situ hybridization. Methods Mol Biol 2011;676:73-83.
72. Nuovo GJ. In situ detection of microRNAs in paraffin embedded, formalin fixed tissues and the co-localization of their putative targets. Methods 2010;52:307-315.
73. Hanna JA, Wimberly H, Kumar S, et al. Quantitative analysis of micro-RNAs in tissue microarrays by in situ hybridization. Biotechniques 2012;52:235-245.
74. Hanna JA, Hahn L, Agarwal S, et al. In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor microRNA. Lab Invest 2012;92:1390-1397.
75. Huang J, Zhou N, Watabe K, et al. Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1). Cell Death Dis 2014;5:e1008.
76. Liu Q, Huang J, Zhou N, et al. LncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res 2013;41:4976-4987.
77. Liu X, Sempere LF, Ouyang H, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010;120:1298-1309.
78. Nie Y, Liu X, Qu S, et al. Long non-coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival. Cancer Sci 2013;104:458-464.
79. Quesne JL, Jones J, Warren J, et al. Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. J Pathol 2012;227:306-314.
80. Sempere LF, Christensen M, Silahtaroglu A, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007;67:11612-11620.
81. Sempere LF, Korc M. A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer. Methods Mol Biol 2013;980:43-59.
82. Yamamichi N, Shimomura R, Inada K, et al. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res 2009;15:4009-4016.
83. Lizardi PM, Huang X, Zhu Z, et al. Mutation detection and singlemolecule counting using isothermal rolling-circle amplification. Nat Genet 1998;19:225-232.
84. Nilsson M, Krejci K, Koch J, et al. Padlock probes reveal singlenucleotide differences, parent of origin and in situ distribution of centromeric sequences in human chromosomes 13 and 21. Nat Genet 1997;16:252-255.
85. Nilsson M, Malmgren H, Samiotaki M, et al. Padlock probes: circularizing oligonucleotides for localized DNA detection. Science 1994;265:2085-2088.
86. Larsson C, Grundberg I, Soderberg O, et al. In situ detection and genotyping of individual mRNA molecules. Nat Methods 2010;7:395-397.
87. Nilsson M, Barbany G, Antson DO, et al. Enhanced detection and distinction of RNA by enzymatic probe ligation. Nat Biotechnol 2000; 18:791-793.
88. Weibrecht I, Lundin E, Kiflemariam S, et al. In situ detection of individual mRNA molecules and protein complexes or post-translational modifications using padlock probes combined with the in situ proximity ligation assay. Nat Protoc 2013;8:355-372.
89. Ke R, Mignardi M, Pacureanu A, et al. In situ sequencing for RNA analysis in preserved tissue and cells. Nat Methods 2013;10:857-860.
90. Fitzgibbons PL, Bradley LA, Fatheree LA, et al. Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med 2014;138:1432-1443.
91. U. S. Food and Drugs AdministrationList of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools) http:// www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ InVitroDiagnostics/ucm301431.htm 2014) Accessed: 22 October 2014.
92. Anagnostou VK, Welsh AW, Giltnane JM, et al. Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev 2010;19:982-991.
93. Bordeaux JM, Cheng H, Welsh AW, et al. Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen. PLoS One 2012;7:e36559.
94. Giltnane JM, Rimm DL. Technology insight: identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol 2004;1:104-111.
95. McCabe A, Dolled-Filhart M, Camp RL, et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97:1808-1815.
96. Welsh AW, Moeder CB, Kumar S, et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol 2011;29:2978-2984.
97. Cheang MC, Treaba DO, Speers CH, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 2006;24:5637-5644.
98. Welsh AW, Harigopal M, Wimberly H, et al. Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5. Appl Immunohistochem Mol Morphol 2013;21:139-147.
99. Brock JE, Hornick JL, Richardson AL, et al. A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results. Am J Clin Pathol 2009;132:396-401.
100. Ratner M. FDA pushes for control over laboratory-developed tests. Nat Biotechnol 2014;32:855.
101. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-1466.
102. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-1452.
103. Gettinger S, Herbst RS. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. Cancer J 2014; 20:281-289.
104. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366: 2443-2454.
105. Schalper KA. PD-L1 expression and tumor-infiltrating lymphocytes: revisiting the antitumor immune response potential in breast cancer. Oncoimmunology 2014;3:e29288.
106. Schalper KA, Velcheti V, Carvajal D, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 2014;20:2773-2782.
107. Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced nonsmall-cell lung cancer. J Clin Oncol 2010;28:918-927.
108. Brown JR, DiGiovanna MP, Killelea B, et al. Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer. Lab Invest 2014;94:98-106.
109. Catenacci DV, Liao WL, Thyparambil S, et al. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One 2014;9:e100586.